ADMA News Alert Adma Biologics (ADMA) 10.90 12/17/2014 04:19

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Adma Biologics (ADMA) 10.90 $ADMA

ADMA Biologics Receives $5M Tranche From Hercules Technology Growth Capital
GlobeNewswire - Mon Dec 15, 7:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. (NYSE:HTGC), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets. The $5 million was based upon ADMA achieving clinical endpoints of a Phase III clinical study of RI-002 as a treatment for Primary Immunodeficiency Disease (PIDD), under its existing loan and security agreement.
HTGC: 14.11 (-0.40), ADMA: 10.90 (-0.09)

ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 325.13 (-10.67), ADMA: 10.90 (-0.09), ANIP: 55.08 (+1.32), AMGN: 159.44 (-0.16)

Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 04, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RDUS: 26.30 (+1.20), IMDZ: 22.15 (+0.35), ADMA: 10.90 (-0.09), MCEP: 6.16 (+0.66), SCYX: 10.10 (+0.06), BOBE: 49.77 (-0.90), HCCI: 10.44 (+0.35), TCCO: 5.31 (+0.60), STRZB: 28.93 (+0.21), STRZA: 27.85 (-0.64)

ADMA Biologics Slumps: ADMA Tanks 11% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:53AM CST
ADMA Biologics has been witnessing a positive trend in its current year estimate revision and its share price has been falling for past few days
BIIB: 325.13 (-10.67), ADMA: 10.90 (-0.09), ANIP: 55.08 (+1.32), AFFX: 8.90 (+0.10)

ADMA lead product successful in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 11:50AM CST

ADMA: 10.90 (-0.09)

ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients
GlobeNewswire - Wed Dec 03, 7:10AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.
ADMA: 10.90 (-0.09)

ADMA Biologics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 3:39PM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the Oppenheimer 25 Annual Healthcare Conference at 10:20 AM ET on December 11, 2014 at the Crowne Plaza Hotel in New York City.
ADMA: 10.90 (-0.09)

ADMA Biologics, Inc. (Nasdaq:ADMA) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Tue Nov 25, 9:19AM CST
What:
ADMA: 10.90 (-0.09), NDAQ: 45.74 (-0.72)

ADMA Biologics Opens Plasma Collection Center in Marietta, Georgia
GlobeNewswire - Tue Nov 18, 6:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), today announced the opening of its second plasma collection facility in Marietta, Georgia.
ADMA: 10.90 (-0.09)

ADMA Biologics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:14AM CST

ADMA: 10.90 (-0.09)

ADMA Biologics to Present at the 9th International Respiratory Syncytial Virus (RSV) Symposium
GlobeNewswire - Mon Nov 10, 6:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), announced today that it will be presenting data describing the composition and efficacy in an animal model of its polyclonal IVIG product, RI-002, at the 9th International Respiratory Syncytial Virus (RSV) Symposium, in Cape Town, South Africa. The abstract is titled: "Treatment of Normal and Immune Suppressed Cotton Rats with IVIG Containing High Titer Neutralizing Anti-RSV Antibody."
ADMA: 10.90 (-0.09)

ADMA Biologics Reports Third Quarter 2014 Financial and Operational Results
GlobeNewswire - Mon Nov 10, 6:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported its financial and operational results for the third quarter ended September 30, 2014 and announced recent Company developments and anticipated milestones for the remainder of 2014.
ADMA: 10.90 (-0.09)

ADMA Biologics Approved for Trading on NASDAQ
GlobeNewswire - Wed Nov 05, 3:38PM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that the NASDAQ stock market has approved ADMA's common stock for listing on the NASDAQ Capital Market and is expected to begin trading on November 10, 2014 under the symbol "ADMA."
ADMA: 10.90 (-0.09)

ADMA Biologics to Present "Ascending Company" Presentation at BioNJ CEO Summit
Business Wire - Thu Oct 16, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the BioNJ CEO Summit Conference at 9:30 AM ET on October 21, 2014 at the Bridgewater Marriott, in Bridgewater, New Jersey.
ADMA: 10.90 (-0.09)

ADMA Biologics' Plasma Collection Subsidiary ADMA BioCenters Norcross, GA Facility Expands Global Regulatory Approval Presence
Business Wire - Wed Sep 10, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its wholly owned subsidiary, ADMA BioCenters in Norcross, Georgia, received approval from the Korean Ministry of Food and Drug Safety (MFDS) for the sale of source plasma into South Korea.
ADMA: 10.90 (-0.09)

ADMA Biologics Reports Second Quarter 2014 Financial and Operational Results
Business Wire - Mon Aug 11, 3:35PM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported its financial and operational results for the second quarter ended June 30, 2014 and announced recent company developments and anticipated milestones for 2014.
ADMA: 10.90 (-0.09)

ADMA Biologics Forms Scientific Advisory Board with Expertise in Immune Deficiencies, Infectious Diseases and Transplantation
Business Wire - Mon Jun 16, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the formation of its Scientific Advisory Board (SAB) with the following appointments: R. Michael Blaese, M.D., Roy F. Chemaly, M.D., M.P.H., John DeVincenzo, M.D., Richard O'Reilly, M.D., Jordan S. Orange, M.D., Ph.D., and E. Richard Stiehm, M.D.
ADMA: 10.90 (-0.09)

ADMA Biologics to Present at 9th Annual JMP Securities Healthcare Conference on June 24
Business Wire - Fri Jun 13, 3:15PM CDT
ADMA Biologics, Inc. (OTCQB: ADMA), a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that Adam Grossman, ADMA's President, Chief Executive Officer and founder, is scheduled to present a company overview at the conference on Tuesday, June 24, 2014 at 12:00 p.m. EDT, at The Westin New York Grand Central Hotel, New York, NY.
ADMA: 10.90 (-0.09)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 112

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 160

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 135

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 157

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 142

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 118

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading

Top 5 Most Recently Viewed Articles

Health-Ade Partners with Wheel of Fortune and Ryan Seacrest

Updated Category News Views 212

Health-Ade Shines at Wheel of Fortune Premiere Health-Ade is thrilled to announce its prominent involvement in the premiere week of the classic game show, Wheel of Fortune, as it embarks on an exciting new journey with Ryan Seacrest as the show's host. This is an exhilarating moment not only for Wheel of Fortune but also for Health-Ade Kombucha, which is celebrated for...

Continue Reading
Investment Fund Trends and Insights for October 2024

Updated Category News Views 101

Mutual Fund and ETF Asset Management In the scope of mutual funds and exchange-traded funds (ETFs), the latest insights reveal a steady growth in assets and sales throughout the investment landscape. As investors look for diverse options, investment funds have shown resilience and dynamic adaptability, showcasing robust growth metrics in their respective categories....

Continue Reading
S&P and Pantera Take Digital Asset Indexing to New Heights

Updated Category News Views 18

Digital Assets: A New Benchmark in Town Date it, folks: July 21, 2026. S&P Dow Jones Indices and Pantera Capital are rolling out a fresh digital asset index. They're slapping the 'S&P Pantera' name on something focused less on the casino vibe you get from memes and Bitcoin mania, and more on actual economic value and real-world use. Flipping the script on the way most of...

Continue Reading
Gundry MD Wins Big with Innovative Softgel Formula

Updated Category News Views 57

Breaking New Ground in Weight Management Forget the caffeine-laden pills and appetite-killer potions—here comes something that simply whispers to your gut and says, "Manage your weight naturally." That's what Gundry MD's Daily Weight Advantage™ has cooked up, bagging the prestigious NutraIngredients-USA's Weight Management Product of 2026 award. Finally, a product...

Continue Reading
Ciena's Options Market Insights: Bullish Trends and Growth Prospects

Updated Category News Views 202

Understanding Ciena's Recent Options Activity Investors with significant resources have shown a clear bullish sentiment towards Ciena (NYSE: CIEN), indicating crucial trends that market observers should consider. By monitoring options records, it’s clear that substantial movements are occurring within the CIEN stock, hinting that noteworthy developments might be on the...

Continue Reading